

**Supplementary Table 1.** Independent Risk Factors for 5-Day Treatment Failure in All Patients with Acute Variceal Hemorrhage (n=329)

Variable	Univariate	Multivariate analysis	
	p-value	p-value	HR (95% CI)
Age	0.052	0.006	1.047 (1.013–1.082)
Initial systolic blood pressure, <100 mm Hg	0.067		
Heart rate <100/min	0.056		
Active bleeding on initial endoscopy	0.001	0.032	2.343 (1.074–5.115)
Endoscopic hemostasis failure	<0.001	0.003	3.555 (1.518–8.326)
PRBC transfusion	0.039		
PPI use	0.034		
Antibiotics prophylaxis	0.029		
MELD score	<0.001		
Presence of HCC	0.002		
Presence of PVT	<0.001		
Presence of ascites	0.003	0.038	3.615 (1.071–12.204)
Hepatic failure	<0.001		
Hepatorenal syndrome	<0.001	0.024	3.228 (1.169–8.914)
Hepatic encephalopathy	<0.001		

HR, hazard ratio; CI, confidence interval; PRBC, packed red blood cell; PPI, proton pump inhibitor; MELD, Model for End-Stage Liver Disease; HCC, hepatocellular carcinoma; PVT, portal vein thrombosis.

**Supplementary Table 2.** Independent Risk Factors for 6-Week Mortality in All Patients with Acute Variceal Hemorrhage (n=329)

Variable	Univariate	Multivariate analysis	
	p-value	p-value	HR (95% CI)
Age	0.059	0.011	1.037 (1.008–1.066)
Initial systolic blood pressure, <100 mm Hg	0.001	0.009	2.592 (1.264–5.315)
Heart rate, <100/min	0.007		
Varix size, ≥F2	0.066	0.002	3.833 (1.634–8.995)
Active bleeding on initial endoscopy	0.001		
Endoscopic hemostasis failure	<0.001	<0.001	5.342 (2.422–11.785)
Alanine aminotransferase	0.012	0.01	1.002 (1.001–1.004)
PPI use	0.007		
Antibiotic prophylaxis	0.014		
MELD score	<0.001	0.001	1.111 (1.042–1.184)
Presence of HCC	<0.001	0.001	2.915 (1.506–5.642)
Presence of ascites	0.002		
Hepatic failure	<0.001	0.001	3.038 (1.540–5.991)
Hepatorenal syndrome	<0.001		

HR, hazard ratio; CI, confidence interval; PPI, proton pump inhibitor; MELD, Model for End-Stage Liver Disease; HCC, hepatocellular carcinoma.